Perspective shows how shared biofluid biorepositories accelerate biomarker discovery in Parkinson's disease, highlighting major benefits for clinical therapeutics.
The recent advent of an "ecosystem" of shared biofluid sample biorepositories and data sets will focus biomarker efforts in Parkinson's disease, boosting the therapeutic development pipeline and enabling translation with real-world impact.
No takes yet. Share an insight, caveat, or question.
Chen‐Plotkin et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: